• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Avid Bioservices Inc.

    8/28/24 4:32:18 PM ET
    $CDMO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CDMO alert in real time by email
    DEFA14A 1 avid_defa14a.htm ADDITIONAL DEFINITIVE MATERIALS

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 14A

     

    Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934

    (Amendment No.    )

     

    Filed by the Registrant ☒

    Filed by a Party other than the Registrant ☐

     

    Check the appropriate box:

     

    ☐ Preliminary Proxy Statement
    ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))
    ☐  Definitive Proxy Statement
    ☒  Definitive Additional Materials
    ☐  Soliciting Material Pursuant to § 240.14a-11(c) or § 240.14a-12

     

    AVID BIOSERVICES, INC.

    (Name of Registrant as Specified In Its Charter)

     

     

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

     

    Payment of Filing Fee (Check the appropriate box):

     

    ☒ No fee required

     

    ☐  Fee paid previously with preliminary materials.

     

    ☐  Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rule 14a-6(i)(1) and 0-11.

     

     

     

     

     

       

     

     

     

     

    Your Vote Counts! *Please check the meeting materials for any special requirements for meeting attendance. Smartphone users Point your camera here and vote without entering a control number For complete information and to vote, visit www.ProxyVote.com Control # V55920 - P16819 AVID BIOSERVICES, INC. C/O BROADRIDGE CORPORATE ISSUER SOLUTIONS P.O. BOX 1342 BRENTWOOD, NY 11717 AVID BIOSERVICES, INC. 2024 Annual Meeting Vote by October 15, 2024 11:59 PM ET You invested in AVID BIOSERVICES, INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy materials for the stockholder meeting to be held on October 16, 2024. Get informed before you vote View the Proxy Statement and Annual Report online OR you can receive a free paper or email copy of the material(s) by requesting prior to October 2, 2024. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1 - 800 - 579 - 1639 or (3) send an email to [email protected]. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. Vote Virtually at the Meeting* October 16, 2024 10:00 AM, Pacific Time Virtually at: www.virtualshareholdermeeting.com/CDMO2024

     
     

     

     

    Vote at www.ProxyVote.com THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters. Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”. For 1. Election of Directors Nominees: 1) Esther M. Alegria, PhD 05) Catherine J. Mackey, PhD 2) Joseph Carleone, PhD 06) Gregory P. Sargen 3) Nicholas S. Green 07) Jeanne A. Thoma 4) Richard B. Hancock For 2. To ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending April 30, 2025. For 3. To approve, by an advisory vote, a non - binding resolution approving the compensation of the Company’s named executive officers, as disclosed in the Company’s proxy statement. For 4. To approve an amendment to the Company’s 2018 Omnibus Incentive Plan to increase the number of shares reserved thereunder. For 5. To approve an amendment to the Company’s 2010 Employee Stock Purchase Plan to remove the expiration date. NOTE: In their discretion, the proxies are authorized to vote upon such other business as may be properly brought before the 2024 Annual Meeting and any adjournment or postponement thereof. Voting Items Board Recommends V55921 - P16819

     

     

    Get the next $CDMO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CDMO

    DatePrice TargetRatingAnalyst
    9/28/2023Mkt Perform
    William Blair
    3/14/2023$20.00Sector Weight → Overweight
    KeyBanc Capital Markets
    3/9/2022$31.00 → $28.00Overweight
    Stephens & Co.
    12/8/2021$29.00 → $35.00Buy
    Craig-Hallum
    12/8/2021$27.00 → $32.00Outperform
    RBC Capital
    12/8/2021Overweight → Sector Weight
    Keybanc
    6/30/2021$21.00 → $29.00Buy
    Craig-Hallum
    6/30/2021$21.00 → $27.00Outperform
    RBC Capital
    More analyst ratings

    $CDMO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    V. P., General Counsel Ziebell Mark R returned 66,799 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - Avid Bioservices, Inc. (0000704562) (Issuer)

    2/7/25 7:40:25 PM ET
    $CDMO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Thoma Jeanne returned 45,611 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - Avid Bioservices, Inc. (0000704562) (Issuer)

    2/7/25 7:40:10 PM ET
    $CDMO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Sargen Gregory returned 36,368 shares to the company, closing all direct ownership in the company (SEC Form 4)

    4 - Avid Bioservices, Inc. (0000704562) (Issuer)

    2/7/25 7:39:57 PM ET
    $CDMO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CDMO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Hancock Richard B bought $202,036 worth of shares (38,803 units at $5.21), increasing direct ownership by 49% to 117,563 units (SEC Form 4)

    4 - Avid Bioservices, Inc. (0000704562) (Issuer)

    1/10/24 7:56:02 PM ET
    $CDMO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hancock Richard B converted options into 9,612 shares and bought $134,734 worth of shares (23,000 units at $5.86), increasing direct ownership by 71% to 78,760 units (SEC Form 4)

    4 - Avid Bioservices, Inc. (0000704562) (Issuer)

    12/18/23 7:31:12 PM ET
    $CDMO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4: Carleone Joseph bought $190,696 worth of shares (20,000 units at $9.53), increasing direct ownership by 27% to 93,956 units

    4 - Avid Bioservices, Inc. (0000704562) (Issuer)

    9/22/23 12:51:46 PM ET
    $CDMO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CDMO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Avid Bioservices Launches New Company Website Designed to Boost Company Brand Awareness and Enhance the Visitor Experience

    TUSTIN, Calif., Feb. 10, 2025 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced the launch of its new corporate website. The new site, which can be visited at www.avidbio.com, combines Avid's elevated brand story and visual identity with improved functionality and navigation, all aimed at enhancing the visitor experience, particularly for current and prospective customers. The reimagined Avid website captures the company's elevated brand throu

    2/10/25 8:05:59 AM ET
    $CDMO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Avid Bioservices, Inc. Provides Notice of Fundamental Change and Make-Whole Fundamental Change to Holders of its Convertible Notes in Connection with Completed Merger

    TUSTIN, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. ("Avid" or the "Company"), a dedicated biologics contract development and manufacturing organization ("CDMO") working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today provided notice (the "Notice") to holders of its 7.00% Convertible Senior Notes due 2029 (the "Notes"), pursuant to the terms of the Indenture, dated as of March 12, 2024 (the "Indenture"), by and between the Company and U.S. Bank Trust Company, National Association ("U.S. Bank"), as trustee, governing the Notes that, in connection with the closing of the transa

    2/5/25 10:45:00 AM ET
    $CDMO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Avid Bioservices poised for significant growth with new partners GHO Capital and Ampersand Capital Partners

    Acquisition of biologics Contract Development and Manufacturing Organisation Avid Bioservices now completedGHO and Ampersand's deep experience in CDMO investing to support Avid's next stage of rapid growth including expanded offerings, talent investment and greater geographic reach LONDON and BOSTON and TUSTIN, Calif., Feb. 05, 2025 (GLOBE NEWSWIRE) -- GHO Capital Partners LLP ("GHO"), the European specialist investor in global healthcare, and Ampersand Capital Partners ("Ampersand"), a private equity firm specialising in growth equity investments in the life sciences and healthcare sectors, today announced the successful closing of the previously announced acquisition of Avid Bioservices

    2/5/25 9:55:00 AM ET
    $CDMO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CDMO
    SEC Filings

    View All

    SEC Form 15-12G filed by Avid Bioservices Inc.

    15-12G - Avid Bioservices, Inc. (0000704562) (Filer)

    2/18/25 6:07:47 AM ET
    $CDMO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 POS filed by Avid Bioservices Inc.

    S-8 POS - Avid Bioservices, Inc. (0000704562) (Filer)

    2/5/25 5:13:38 PM ET
    $CDMO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 POS filed by Avid Bioservices Inc.

    S-8 POS - Avid Bioservices, Inc. (0000704562) (Filer)

    2/5/25 5:13:36 PM ET
    $CDMO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CDMO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    William Blair initiated coverage on Avid Bioservices

    William Blair initiated coverage of Avid Bioservices with a rating of Mkt Perform

    9/28/23 8:08:44 AM ET
    $CDMO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Avid Bioservices upgraded by KeyBanc Capital Markets with a new price target

    KeyBanc Capital Markets upgraded Avid Bioservices from Sector Weight to Overweight and set a new price target of $20.00

    3/14/23 7:17:41 AM ET
    $CDMO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Stephens & Co. reiterated coverage on Avid Bioservices with a new price target

    Stephens & Co. reiterated coverage of Avid Bioservices with a rating of Overweight and set a new price target of $28.00 from $31.00 previously

    3/9/22 6:57:34 AM ET
    $CDMO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CDMO
    Leadership Updates

    Live Leadership Updates

    View All

    Uber Technologies, Jabil and Builders FirstSource Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

    NEW YORK, Dec. 1, 2023 /PRNewswire/ -- S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, December 18, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap market space, and all companies being added to the S&P SmallCap 600 are more representative of the small-cap market space. The companies being removed from t

    12/1/23 6:16:00 PM ET
    $ALK
    $ALKS
    $AWI
    Air Freight/Delivery Services
    Consumer Discretionary
    Biotechnology: Pharmaceutical Preparations
    Health Care

    STERIS Appoints Esther M. Alegria, Ph.D. to Board of Directors

    DUBLIN, IRELAND, May 03, 2023 (GLOBE NEWSWIRE) -- STERIS plc (NYSE:STE) ("STERIS" or the "Company") announced today that Esther M. Alegria, Ph.D. has been elected to the Board of Directors, effective today. "We are pleased to welcome Dr. Alegria to our Board," said Mohsen Sohi, Chairman of STERIS. "She brings over three decades of experience in the biopharmaceuticals industry to our Board and will be a valuable addition." Dr. Alegria is the Founder and Chief Executive Officer of APIE Therapeutics, where she leads a team focused on the development of therapeutic drugs to treat chronic and debilitating diseases. Prior to APIE, Dr. Alegria was President and Senior Executive Advisor at Catal

    5/3/23 4:30:00 PM ET
    $CDMO
    $STE
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Industrial Specialties

    Avid Bioservices Appoints Oksana Lukash as Vice President, People

    TUSTIN, Calif., Nov. 16, 2022 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced the appointment of Oksana Lukash, as vice president, people. Ms. Lukash has more than 20 years of human resources experience with both established and entrepreneurial organizations across a range of industries. Prior to joining Avid, Ms. Lukash served as vice president, people & culture at Oncocyte Corporation, a precision diagnostics company. During her three year

    11/16/22 8:05:00 AM ET
    $CDMO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CDMO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Avid Bioservices Inc.

    SC 13G - Avid Bioservices, Inc. (0000704562) (Subject)

    12/13/24 10:53:25 AM ET
    $CDMO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Avid Bioservices Inc.

    SC 13G/A - Avid Bioservices, Inc. (0000704562) (Subject)

    11/14/24 7:53:01 PM ET
    $CDMO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Avid Bioservices Inc.

    SC 13G/A - Avid Bioservices, Inc. (0000704562) (Subject)

    11/12/24 4:15:31 PM ET
    $CDMO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CDMO
    Financials

    Live finance-specific insights

    View All

    Avid Bioservices Reports Financial Results for Second Quarter Ended October 31, 2024

    TUSTIN, Calif., Dec. 10, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced financial results for the second quarter and six months ended October 31, 2024. Highlights from the Quarter Ended October 31, 2024: "We delivered solid results in a competitive environment, with increased revenues and backlog offset by increased costs," stated Nick Green, president and CEO of Avid Bioservices. "We are pleased to reach the separately announced agre

    12/10/24 4:05:23 PM ET
    $CDMO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Avid Bioservices Reports Financial Results for First Quarter Ended July 31, 2024

    -- Recorded First Quarter Revenue of $40.2 Million -- -- Signed $66 Million in Net New Business, Resulting in Backlog of $219 Million -- -- Maintained FY2025 Revenue Guidance of Between $160 Million and $168 Million -- TUSTIN, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced financial results for the first quarter ended July 31, 2024. Highlights from the Quarter Ended July 31, 2024, and Other Events:

    9/9/24 4:05:31 PM ET
    $CDMO
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Avid Bioservices to Report Financial Results for First Quarter of Fiscal Year 2025 After Market Close on September 9, 2024

    TUSTIN, Calif., Sept. 03, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ:CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality services to biotechnology and pharmaceutical companies, today announced that it will report financial results for the first quarter of fiscal year 2025 on September 9, 2024, after market close and will host a webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time). Members of Avid's senior management will discuss financial results for the first quarter and review recent corporate developments. To listen to the live webcast, or access the archived webcast, please

    9/3/24 4:05:20 PM ET
    $CDMO
    Biotechnology: Pharmaceutical Preparations
    Health Care